A Phase IIb Randomized Double-Blinded Positive Controlled Trial to Evaluate the Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults Who Have Completed Two Doses of CoronaVac® or the mRNA Vaccine (Comirnaty) in Turkey
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- COVID-19
- Sponsor
- Sinovac Research and Development Co., Ltd.
- Enrollment
- 640
- Locations
- 2
- Primary Endpoint
- Immunogenicity index-GMT of neutralizing antibodies
- Status
- Suspended
- Last Updated
- 3 years ago
Overview
Brief Summary
This is a randomized, double-blinded, and positive-controlled Phase IIb clinical trial of COVID-19 vaccine (CoronaVac®) manufactured by Sinovac Research & Development Co., Ltd.The purpose of this study is to evaluate the immunogenicity of using the high (1200SU) or medium (600SU) dose of CoronaVac® as the booster dose.
Detailed Description
This is a randomized, double-blinded, and positive-controlled phaseⅡb clinical trial of 640 participants aged 18 years and above, who have completed 2 doses of inactivated COVID-19 vaccine (CoronaVac®) or mRNA COVID-19 vaccine (Comirnaty) as the primary vaccination. Participants will be enrolled and randomly assigned into two arms at a ratio of 1:1 to receive a booster dose of medium-dose (600SU) or high-dose (1200SU) COVID-19 Vaccine. For those who were vaccinated with CoronaVac®, the booster dose will be given 3-8 months after their second dose. For those who were vaccinated with Comirnaty, the booster dose will be given 6-8 months after their second dose. Each participant will be collected 5.0 ml blood sample before vaccination and 14 days,3 months and 6 months after booster immunization.Immunogenicity assessments will be determined by neutralizing antibodies in all participants.In addition,all participants will be monitored for immediate reactions (within 30 minutes) after the booster dose vaccination, adverse events of special interest (AESIs) and serious adverse events (SAEs) for 12 months after booster dose inoculation. In addition, all participants in will be monitored for local and systemic solicited adverse events (AEs) within 7 days and the unsolicited AEs within 28 days.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy adults aged 18 years and above, who have received 2 prior doses of inactivated COVID-19 vaccine (CoronaVac®) or mRNA COVID-19 vaccine (Comirnaty), with the second dose given 3-8 months (for CoronaVac® recipients) and 6-8 months (for Comirnaty recipients) prior to the day of booster vaccination in the present study;
- •Antigen rapid testing negative at the day of enrollment on site or with a PCR negative result within 72 hours before enrollment;
- •The participants are able to understand and sign the informed consent voluntarily;
- •Female participants who have a negative pregnancy test on the day of vaccination, and not currently breastfeeding;
- •The participants are planning to be living in Turkey for the following 1 year after attending this study;
- •The participants must be willing to provide verifiable identification (in accordance with the local regulations), has means to be contacted and to contact the investigator during the study.
Exclusion Criteria
- •History of confirmed or currently with the infection of SARS-CoV-2 prior to randomization;
- •Any prior administration of another investigational coronavirus vaccine or current/planned simultaneous participation in another interventional study to prevent or treat COVID-19;
- •Known allergy to vaccines or vaccine ingredients, and serious adverse reactions to vaccines, such as urticaria, dyspnea, angioneurotic edema;
- •Serious chronic disease, serious cardiovascular disease, hypertension and diabetes that cannot be controlled by drugs, hepatorenal disease, malignant tumor, etc;
- •Acute central nervous system diseases such as encephalitis/myelitis, acute disseminating encephalomyelitis, and related disorders;
- •Receipt of blood/plasma products or immunoglobulins in the past 3 months before vaccination in this study;
- •Participation in other studies involving study intervention within 30 days prior to vaccination in this study;
- •Receipt of attenuated live vaccines in the past 14 days prior to vaccination in this study;
- •Receipt of inactivated or subunit vaccines in the past 7 days prior to vaccination in this study;
- •Acute exacerbation or presentation of stable chronic diseases (including but not limited to asthma, migraine, gastrointestinal disorder, etc.);
Outcomes
Primary Outcomes
Immunogenicity index-GMT of neutralizing antibodies
Time Frame: 14 days (14-28 days) after the booster dose vaccination
GMT of neutralizing antibodies on 14 days (14-28 days) after the booster dose vaccination
Secondary Outcomes
- Immunogenicity index-Seropositivity rate of neutralizing antibodies(14 days (14-28 days) after the booster dose vaccination)
- Safety index-Occurrence, intensity, duration, and relationship of solicited local and systemic AEs(7 days following the booster dose vaccination)
- Immunogenicity index-The seropositivity rate of neutralizing antibody(At 3 (±2 weeks) and 6 (±2 weeks) months after the booster dose vaccination)
- Immunogenicity index-GMI of neutralizing antibodies(14 days (14-28 days) after the booster dose vaccination)
- Immunogenicity index-GMT of neutralizing antibody(At 3 (±2 weeks) and 6 (±2 weeks) months after the booster dose vaccination)
- Safety index-Occurrence and relationship of SAEs(From the booster dose to 12 months post booster vaccination)
- Safety index-Occurrence, intensity, duration, and relationship of unsolicited AEs(28 days post booster vaccination)
- Safety index-Occurrence and relationship of AESI(From the booster dose to 12 months post booster vaccination)